Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective phase II trial of docetaxel-samarium in patients with
hormone-refractory advanced prostate cancer who achieve a response or a stabilization to
docetaxel-estramustine.